Structure Therapeutics Inc. (GPCR)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end position value increased by $6.26 million due to the new holding.
Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%
The stock's rise comes as the company reported significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity, while broader markets experienced mixed movements.
Structure Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 1.43M | $29.71M | $66.87M | $37.16M | 125.07% |
 David Kim Paradigm Biocapital Advisors LP | 545,287 | $26.28M | $25.3M | -$984,243.04 | -3.74% |
| NM Nir Messafi Deep Track Capita LLP | 4.28M | $103.59M | $198.56M | $94.97M | 91.68% |
| MPM Mark P. Mennitt CenterBook Partners LP | 21,237 | $1.02M | $992,989.03 | -$30,634.37 | -2.99% |
 Regan O'Neill Burkehill Global Management LP | 60,000 | $4.17M | $2.85M | -$1.33M | -31.82% |
Structure Therapeutics Inc. (GPCR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Structure Therapeutics Inc. ever had a stock split?
Structure Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Raymond C. Stevens CEO | NASDAQ (NMS) Exchange | 86366E106 CUSIP |
| US Country | 233 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Structure Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the global development and commercialization of novel oral therapeutics for the treatment of chronic diseases that currently lack adequate medical solutions. The company, originally known as ShouTi Inc. before its rebranding, was founded in 2016 and has its headquarters in South San Francisco, California. With a mission to address unmet medical needs, Structure Therapeutics is at the forefront of discovering and developing innovative treatments that can be administered orally, offering potential ease-of-use and improved quality of life for patients suffering from various chronic conditions.
Products and Services
- GSBR-1290
- ANPA-0073
- LTSE-2578
An advanced oral small molecule therapy, GSBR-1290, serves as the company's leading product candidate. This drug is specifically designed as a biased agonist of the glucagon-like-peptide-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR) recognized for its efficacy in the treatment of type-2 diabetes mellitus and obesity. By targeting this validated receptor, GSBR-1290 exemplifies the company's commitment to introducing novel therapeutic options for these widespread and impactful health concerns.
As part of its portfolio targeting GPCRs, Structure Therapeutics is developing ANPA-0073, a biased agonist directed at the apelin receptor, another GPCR. The apelin receptor has been implicated in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterized by a progressive decline in lung function. By focusing on this target, ANPA-0073 is at the cutting edge of research for new treatments aimed at IPF, a condition for which current therapeutic options are limited and the need for innovative solutions is high.
LTSE-2578 represents another facet of the company's dedication to addressing pulmonary and cardiovascular diseases through the development of oral small molecule therapeutics. This investigational compound is a lysophosphatidic acid 1 (LPA1) receptor antagonist, geared towards treating idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic diseases. By targeting the LPA1 receptor, LTSE-2578 is aimed at mitigating fibrotic processes, offering hope for treatments in areas where few options currently exist.
